Scorpion Biological Services, a biopharmaceutical contract development and manufacturing organization (CDMO) and contract research organization (CRO), has appointed Stephan Kutzer as its interim chief executive officer. He currently serves on Scorpion’s advisory board.

Dr. Kutzer brings more than 25 years of experience in the pharmaceutical and biotech industries, managing successful contract development and manufacturing organizations. He previously served as president and CEO of Alcami Corporation, a provider of development, analytical testing, and manufacturing services to the pharmaceutical and biotech industries. Prior to this, he served as president, divisional CEO and chief operating officer of the pharma biotech and customer manufacturing division of Lonza Group, where he had full oversight of the division, which generated over $1.6 billion in annual sales.

Dr. Kutzer also served as a member of the executive management board of Lonza Group; president of Lonza Biologics; chairman of the board of directors of Lonza Singapore; chairman of the board of directors of Teva-Lonza TL Biopharmaceuticals; chairman of the board of directors of Lonza Biologics; and president and chairman of Lonza Inc. He previously served as an executive director on the board of directors for the Drug, Chemical & Associated Technologies Association (DCAT). Dr. Kutzer earned a master’s degree in chemical and process engineering and a Ph.D. in engineering sciences from the Technical University of Munich, Germany.

“With the rapid growth of Scorpion and the announcement of our new commercial-scale biomanufacturing facility in Manhattan, KS, Scorpion welcomes Stephan to this position,” said David Halverson, president of Scorpion Biological Services. “We look forward to advancing into our next phase of growth under his stewardship.”

Commenting on his appointment, Dr. Kutzer said, “This is an exciting time at Scorpion as we seek to build a robust and fully integrated CDMO. I am honored to have this opportunity and look forward to supporting Scorpion through this next phase of growth.”